Mozobil®(Plerixafor, AMD3100), 10 years after its approval by the US Food and Drug Administration

E De Clercq - Antiviral Chemistry and Chemotherapy, 2019 - journals.sagepub.com
AMD3100 (plerixafor, Mozobil®) was first identified as an anti-HIV agent specifically active
against the T4-lymphotropic HIV strains, as it selectively blocked the CXCR4 receptor …

CXCL12/CXCR4 signal transduction in diseases and its molecular approaches in targeted-therapy

A Mousavi - Immunology Letters, 2020 - Elsevier
Chemokines are small molecules called “chemotactic cytokines” and regulate many
processes like leukocyte trafficking, homing of immune cells, maturation, cytoskeletal …

A phase III randomized crossover trial of plerixafor versus G-CSF for treatment of WHIM syndrome

DH McDermott, D Velez, E Cho… - The Journal of …, 2023 - Am Soc Clin Investig
BACKGROUND Warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM)
syndrome is a primary immunodeficiency disorder caused by heterozygous gain-of-function …

The WHIM-like CXCR4S338X somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom's …

Y Cao, ZR Hunter, X Liu, L Xu, G Yang, J Chen… - Leukemia, 2015 - nature.com
CXCR4 WHIM somatic mutations are common Waldenstrom's Macroglobulinemia (WM), and
are associated with clinical resistance to ibrutinib. We engineered WM cells to express the …

[HTML][HTML] Mobilization-based chemotherapy-free engraftment of gene-edited human hematopoietic stem cells

A Omer-Javed, G Pedrazzani, L Albano, S Ghaus… - Cell, 2022 - cell.com
Hematopoietic stem/progenitor cell gene therapy (HSPC-GT) is proving successful to treat
several genetic diseases. HSPCs are mobilized, harvested, genetically corrected ex vivo …

Plerixafor for the treatment of WHIM syndrome

DH McDermott, DV Pastrana, KR Calvo… - … England Journal of …, 2019 - Mass Medical Soc
WHIM syndrome (warts, hypogammaglobulinemia, infections, and myelokathexis), a primary
immunodeficiency disorder involving panleukopenia, is caused by autosomal dominant gain …

WHIM syndrome: from pathogenesis towards personalized medicine and cure

LE Heusinkveld, S Majumdar, JL Gao… - Journal of clinical …, 2019 - Springer
WHIM syndrome is a rare combined primary immunodeficiency disease named by acronym
for the diagnostic tetrad of warts, hypogammaglobulinemia, infections, and myelokathexis …

A phase 1 clinical trial of long-term, low-dose treatment of WHIM syndrome with the CXCR4 antagonist plerixafor

DH McDermott, Q Liu, D Velez, L Lopez… - Blood, The Journal …, 2014 - ashpublications.org
Warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome is a rare
immunodeficiency disorder caused by gain-of-function mutations in the G protein–coupled …

Results of a phase 2 trial of an oral CXCR4 antagonist, mavorixafor, for treatment of WHIM syndrome

DC Dale, F Firkin, AA Bolyard, M Kelley… - Blood, The Journal …, 2020 - ashpublications.org
Warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome is a rare
primary immunodeficiency caused by gain-of-function mutations in the CXCR4 gene. We …

ACKR3 regulation of neuronal migration requires ACKR3 phosphorylation, but not β-arrestin

F Saaber, D Schütz, E Miess, P Abe, S Desikan… - Cell reports, 2019 - cell.com
Phosphorylation of heptahelical receptors is thought to regulate G protein signaling, receptor
endocytosis, and non-canonical signaling via recruitment of β-arrestins. We investigated …